Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2005
12/01/2005US20050267185 1,2,4-triazole derivatives, compositions, process of making and methods of use
12/01/2005US20050267183 Selective estrogen receptor modulators
12/01/2005US20050267165 Il-8 receptor antagonists
12/01/2005US20050267163 Vanilloid receptor ligands and their use in treatments
12/01/2005US20050267155 Constrained himbacine analogs as thrombin receptor antagonists
12/01/2005US20050267137 Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof
12/01/2005US20050267133 Pyrazolopyrimidines as kinase inhibitors
12/01/2005US20050267129 Dipeptide nitrile cathepsin K inhibitors
12/01/2005US20050267126 Compounds derived from aryl carbamates, preparation thereof and uses of same
12/01/2005US20050267123 6-Membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
12/01/2005US20050267122 Ansamycins having improved pharmacological and biological properties
12/01/2005US20050267118 Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
12/01/2005US20050267114 Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
12/01/2005US20050267112 intravenous or oral administration; hypotensive agents; enzyme inhibitors of cGMP-metabolizing phosphodiesterases
12/01/2005US20050267097 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
12/01/2005US20050267062 Endothelial growth factors; antiischemic agents; neovascularization
12/01/2005US20050267049 Anti-hypercholesterolemic compounds
12/01/2005US20050267038 Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
12/01/2005US20050267024 Polypeptide, cancer therapy, neovascularization defects, retinopathies, arthritis and psoraisis
12/01/2005US20050266549 Molecular switch for regulating mammalian gene expression
12/01/2005US20050266533 Therapeutic fusion protein with enhanced for use in prevention and treatment of cell proliferative, blood and nervous system disorders
12/01/2005US20050266532 Albumin fusion proteins
12/01/2005US20050266426 Confluence regulated adhesion molecules useful in modulating vascular permeability
12/01/2005US20050266062 Percutaneous absorption preparation containing 3-methyl-1-phenyl-2-pyrazolin-5-one
12/01/2005US20050266033 Generation of therapeutic microfoam
12/01/2005US20050265987 Sulfatases and methods of use thereof
12/01/2005US20050265976 Method of differentiation of morula or inner cell mass cells and method of making lineage-defective embryonic stem cells
12/01/2005US20050265969 Therapeutic chemokine receptor antagonists
12/01/2005DE102004022383A1 New pyridopyrazine derivatives are modulators of kinase activity, useful for the treatment of diseases associated with abnormal cellular signaling, e.g. tumors
12/01/2005CA2566466A1 Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists
12/01/2005CA2565029A1 Immediate release pharmaceutical tablets with height greater than width
11/2005
11/30/2005EP1600511A1 Method of treating ischemic disease
11/30/2005EP1600445A1 Medicinal composition
11/30/2005EP1600441A2 Novel crystalline form of lercanidipin hydrochloride and processes for its preparation
11/30/2005EP1600440A1 Indole derivative compounds and drugs containing the compounds as the active ingredient
11/30/2005EP1600180A2 Antiproliferative drug and delivery device
11/30/2005EP1600165A1 Medicinal use of mip-3alpha inhibitor and method of screening brain/nerve cell protective agent
11/30/2005EP1600163A1 Use of the neurotoxic component of botulinum toxins for the treatment of spastic muscle
11/30/2005EP1599600A2 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A2 (PDE7a2)
11/30/2005EP1599503A2 Endothelial cell specific antibodies and uses thereof
11/30/2005EP1599455A1 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis
11/30/2005EP1599453A1 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
11/30/2005EP1599452A1 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
11/30/2005EP1599198A1 Potassium taurate bicarbonate and ascorbate complexes
11/30/2005EP1458381B1 Triazoles as oxytocin antagonists
11/30/2005EP1432708B1 Preparation and use of 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine derivatives for treatment of obesity
11/30/2005EP1392337B1 Pharmaceutical formulation consisting of a plant dry extract with a calcium coating
11/30/2005EP1317483B1 Variants of allergenic proteins of the group 2 of dermatophagoides
11/30/2005EP1313488A4 Compositions and methods for improving cardiovascular function
11/30/2005EP1289534B1 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
11/30/2005EP1221941A4 Powder pharmaceutical formulations
11/30/2005EP1212314B1 Benzopyran derivative
11/30/2005EP1176981B1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/30/2005EP1173418B1 Crystalline form 3 of the sodium salt of 5- chloro -2- methoxy -n- (2- (4-methoxy -3- methyl aminothio carbonylamino sulfonylphenyl) ethyl) benzamide
11/30/2005EP1144372B1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
11/30/2005EP1091943B1 Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
11/30/2005EP0963200B9 Compositions for inhibition of angiogenesis comprising thalodomide and a nsaid
11/30/2005EP0932403B1 Condensed (hetaryl-substituted) 1-benzyl-3-pyrazol derivates for treating diseases of the cardiovascular and central nervous systems
11/30/2005EP0888341B1 Novel sulphur derivatives comprising an amide bond, method for preparing same, use thereof as drugs, and pharmaceutical compositions containing such derivatives
11/30/2005CN1703425A Crystallization of IGF-1
11/30/2005CN1703420A Promoters exhibiting endothelial cell specificity and methods of using same
11/30/2005CN1703410A Isoquinoline compounds and medicinal use thereof
11/30/2005CN1703403A Metabotropic glutamate receptor antagonists
11/30/2005CN1703401A Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
11/30/2005CN1703395A Aryl and heteroaryl compounds and methods to modulate coagulation
11/30/2005CN1703234A The use of low-molecular-weight thrombin inhibitor
11/30/2005CN1703197A Injectable depot compositions and uses thereof
11/30/2005CN1702070A N-benzyl acryloyl substituted tyrosine derivatives as hPPAR alpha and hPPAR gamma agonist
11/30/2005CN1229390C Peptides that lower blood glucose levels
11/30/2005CN1229388C N-terminal modified protein compositions and methods therefor
11/30/2005CN1229377C Spiro [Piperidine-4,1'-pyrrolo[3,4-c] pyrrole]
11/30/2005CN1229375C Nicotinic acetylcholine receptor inhibitor, its prepn. and application
11/30/2005CN1229373C Piperidinee derivatives as neurokinin1 antagonists
11/30/2005CN1229371C Benzopyranyl guanidine derivtives, process for preparation thereof and pharmaceutical compositions containing them
11/30/2005CN1229362C Bicyclic guanidine derivatives and therapeutic uses thereof
11/30/2005CN1229353C Method and compositions utilizing quinazolinones
11/30/2005CN1229351C Heterocyclic compounds and methods to treat cardiac failure and other disorders
11/30/2005CN1229350C New azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias
11/30/2005CN1229349C Pyridine-3-carboxylic acid derivative
11/30/2005CN1229343C Chemotactic factor receptor active regulator
11/30/2005CN1229335C Nervinolin derivatives
11/30/2005CN1229324C Extraction process of tanshin general phenolic acid and its prepn and use
11/30/2005CN1229141C Combination therapy of angiotension converting enzyme inhibitor and epoxy-steroidal aldosterone anatagonist for treatment of cardiovascular disease
11/30/2005CN1229137C New therapeutic uses of SMR1 peptides
11/30/2005CN1229128C Detoxification tea of white bamboo
11/30/2005CN1229127C Medicinal composition for preventing and curing hypertension and its preparing method
11/30/2005CN1229122C Combination of Chinese herbal medicine for treating high blood pressure
11/30/2005CN1229031C Improved bioactive whey protein hydrolysate
11/29/2005US6969770 reacting an alpha-keto carboxy acid ester or derivative with a pyrrolidinone to form an intermediate, subjecting the intermediate to asymmetric hydrogenation using a chiral catalyst to form the end product
11/29/2005US6969729 An indole or benz(g)indole-2,3-dione-3-oxime compounds; therapeutic treatment of respiratory disorders, urogenital disorders, cardiovascular disorders, brain and psychological disorders, gastrointestinal disorders
11/29/2005US6969728 Antiinflammatory agents
11/29/2005US6969727 Obesity; osteoporosis
11/29/2005US6969724 Compounds
11/29/2005US6969723 preferably antagonists used in the therapeutic and/or preventive treatment of disfunctions of the heart, kidney, respiratory system, central nervous system
11/29/2005US6969719 Such as 3-((3-bromo-4-hydroxyphenyl)methyl)-5-ethyl-7,8-dihydro-2-(tetrahydro-2H -pyran-4-yl)amino)-3H-imidazo(2,1-b) purin-4(5H)-one for treating sexual disorders
11/29/2005US6969717 Azaindole kinase inhibitors
11/29/2005US6969715 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
11/29/2005US6969714 Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
11/29/2005US6969712 Alzheimer's disease; central nervous system disorders; antidepressants; antidiabetic agents; analgesics
11/29/2005US6969707 For therapy or inhibiting the development of a pathology associated with peroxynitrite damage
1 ... 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 ... 1595